Andrea van Elsas, an immuno-oncology expert who directed some of the earliest research on pembrolizumab, has joined the supervisory board of DCprime BV to help oversee the company’s relapse vaccines which are intended to delay the recurrence of disease. Dr van Elsas is currently chief scientific officer of Aduro Biotech, Inc. He also serves on the board of Lava Therapeutics BV and on the scientific advisory board of InteRNA Technologies BV.
Also joining the DCprime supervisory board is Hans Preusting, chief executive of Synerkine Pharma BV which develops fusion proteins for the treatment of chronic pain.
DCprime announced the appointments on 25 April 2019.
Copyright 2019 Evernow Publishing Ltd.